Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward J Fox

Showing results (91-100 of 127) with videos related to

Pageof 13
Sort By:
Neurology|August 12, 2016
The 11-year long-term follow-up study from the randomized BENEFIT CIS trialLudwig Kappos, Gilles Edan, Mark S Freedman, et al.
Brain : a Journal of Neurology|July 28, 2010
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunityJoanne L Jones, Jane M Anderson, Chia-Ling Phuah, et al.
Cancer Letters|December 30, 2008
Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosisAlan Coss, Miriam Tosetto, Edward J Fox, et al.
Research Square|March 11, 2024
Heparin-enriched plasma proteome is significantly altered in Alzheimer's DiseaseQi Guo, Lingyan Ping, Eric B Dammer, et al.
Biorxiv : the Preprint Server for Biology|March 31, 2025
Proteomic Subtyping of Alzheimer's Disease CSF links Blood-Brain Barrier Dysfunction to Reduced levels of Tau and Synaptic BiomarkersMadison C Bangs, Joshna Gadhavi, E Kathleen Carter, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 3, 2025
Proteomic subtyping of Alzheimer's disease CSF links blood-brain barrier dysfunction to reduced levels of tau and synaptic biomarkersMadison C Bangs, Joshna Gadhavi, E Kathleen Carter, et al.
JAMA Neurology|August 28, 2020
Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical TrialBruce A C Cree, Myla D Goldman, John R Corboy, et al.
Medrxiv : the Preprint Server for Health Sciences|October 3, 2025
CSF proteogenomics implicates novel proteins and humoral immunity in Alzheimer's disease riskAliza P Wingo, Yue Liu, Zhen Mei, et al.
Molecular Neurodegeneration|October 8, 2024
Heparin-enriched plasma proteome is significantly altered in Alzheimer's diseaseQi Guo, Lingyan Ping, Eric B Dammer, et al.
Parkinsonism & Related Disorders|July 8, 2022
Parkinson's Progression Markers Initiative brain autopsy programSyed A Bukhari, Kelly N H Nudelman, Malia Rumbaugh, et al.
Pageof 13

Showing results (91-100 of 127) with videos related to

Sort By:
Pageof 13
Neurology|August 12, 2016
The 11-year long-term follow-up study from the randomized BENEFIT CIS trialLudwig Kappos, Gilles Edan, Mark S Freedman, et al.
Brain : a Journal of Neurology|July 28, 2010
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunityJoanne L Jones, Jane M Anderson, Chia-Ling Phuah, et al.
Cancer Letters|December 30, 2008
Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosisAlan Coss, Miriam Tosetto, Edward J Fox, et al.
Research Square|March 11, 2024
Heparin-enriched plasma proteome is significantly altered in Alzheimer's DiseaseQi Guo, Lingyan Ping, Eric B Dammer, et al.
Biorxiv : the Preprint Server for Biology|March 31, 2025
Proteomic Subtyping of Alzheimer's Disease CSF links Blood-Brain Barrier Dysfunction to Reduced levels of Tau and Synaptic BiomarkersMadison C Bangs, Joshna Gadhavi, E Kathleen Carter, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 3, 2025
Proteomic subtyping of Alzheimer's disease CSF links blood-brain barrier dysfunction to reduced levels of tau and synaptic biomarkersMadison C Bangs, Joshna Gadhavi, E Kathleen Carter, et al.
JAMA Neurology|August 28, 2020
Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical TrialBruce A C Cree, Myla D Goldman, John R Corboy, et al.
Medrxiv : the Preprint Server for Health Sciences|October 3, 2025
CSF proteogenomics implicates novel proteins and humoral immunity in Alzheimer's disease riskAliza P Wingo, Yue Liu, Zhen Mei, et al.
Molecular Neurodegeneration|October 8, 2024
Heparin-enriched plasma proteome is significantly altered in Alzheimer's diseaseQi Guo, Lingyan Ping, Eric B Dammer, et al.
Parkinsonism & Related Disorders|July 8, 2022
Parkinson's Progression Markers Initiative brain autopsy programSyed A Bukhari, Kelly N H Nudelman, Malia Rumbaugh, et al.
Pageof 13